Prosecution Insights
Last updated: November 20, 2026
Application No. 18/332,933

Hybridization Chain Reaction Methods for In Situ Molecular Detection

Non-Final OA §103
Filed
Jun 12, 2023
Priority
Apr 25, 2016 — provisional 62/326,959 +3 more
Examiner
KAPUSHOC, STEPHEN THOMAS
Art Unit
1683
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
President and Fellows of Harvard College
OA Round
1 (Non-Final)
47%
Grant Probability
Moderate
1-2
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
347 granted / 745 resolved
-13.4% vs TC avg
Strong +54% interview lift
Without
With
+53.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
58 currently pending
Career history
826
Total Applications
across all art units

Statute-Specific Performance

§101
23.3%
-16.7% vs TC avg
§103
22.4%
-17.6% vs TC avg
§102
11.3%
-28.7% vs TC avg
§112
34.5%
-5.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 745 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of the particular species that are: chemical treatment for degrading an amplicon (relevant to claim 74); nucleic acid target analyte (relevant to claims 83 and 84); and signal detection by sequencing by hybridization (relevant to claim 90) in the reply filed on 08/18/2026 is acknowledged. In light of the Examiners search and examination of the elected “chemical” treatment for degrading an amplicon, the species election requirement as it was applied to the election of a degradation treatment selected from chemical, enzymatic, or light (relevant to claim 74) is withdrawn. Claims 85 (drawn to non-elected protein analytes), 86 (drawn to non-elected lipid, metabolite or small molecule analytes), 88 (drawn to non-elected sequencing by synthesis), and 89 (drawn to non-elected sequencing by ligation) are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/18/2026. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 71-84, 87 and 90 is/are rejected under 35 U.S.C. 103 as being unpatentable over Choi et al (2014) (NPL citation 36 on the IDS of 06/12/2023) including the Supplementary Material, in view of Cai et al (US PG Pub 2015/0267251; US Patent Application citation 97 on the IDS of 06/12/2023). Relevant to the methods of instantly rejected claim 71, Choi et al teaches associating a plurality of primary probes (relevant to claims 79, 80 and 81) to an mRNA target analyte (relevant to claims 83 and 84), where the primary probe has a structure that includes first and second linkers located at the 5’ and the 3’ end of the each primary probe (relevant to claim 72) (e.g.: Figure 1). The primary probes of Choi et al include distinct linker sequences (i.e.: the initiators I1 and I2 of Choi et al) that together provide for the identification of the primary probe (relevant to claim 76 and 77) (e.g.: Supplementary Material S5). Choi et al teaches detection of the primary probe by hybridization with metastable fluorescently-labeled hairpins (e.g.: the HCR amplifier sequences Supplementary Material S6) to generate labeled hybridization chain reaction amplicons that are detected by their labels (e.g.: Figure 1) (relevant to claims 75), including in situ detection of targets (e.g.: Figure 7) (relevant to claim 90). Choi et al does not exemplify methods in which a least a portion of a first HCT amplicon coupled to a primary probe is removed form the primary probe. However, the sequential analysis of bound probes, including the removal of a first bound probe prior to the hybridization and detection of a second bound probe, was known in the prior art and is taught by Cai et al. Relevant to the limitations of the instantly rejected claims, Cai et al teaches methods for the detection of mRNA analytes using a plurality of fluorescently labeled probes. Cai et al exemplifies the hybridization and detection of a first fluorescently labeled probe, followed by the removal of the probe using enzymatic digestion and photobleaching, and subsequent hybridization and detection of a second spectrally distinct fluorescently labeled probe (e.g.: Figure 2, Figure 3; paras 0210-0229) to identify target nucleic acids (relevant to the limitations of claims 71, 73, 74, 77, 78 and 82). It would have been prima facie obvious to someone with ordinary skill in the relevant art before the effective filing date of the rejected claims to performed the sequential hybridization techniques of Cai et al using the primary probes with multiple linker domains as taught by Choi et al. The skilled artisan would have been motivated to use the particular structures of Choi et al because the skilled artisan would recognize that having multiple targets for metastable fluorescently-labeled hairpins would expand the ability of the barcoding detection of Cai et al by providing more labeled-probe binding sites. The skilled artisan would have a reasonable expectation of success because Cai et al teaches the use of hybridization chain reaction probes (e.g.: Figs 21-23; para 0106; para 0148). With regard to the limitations of claim 79, where Choi et al exemplifies the use of primary probes with two linker domains on each probe, and Cai et al exemplifies the detection of a target by barcoding with a plurality of spectrally distinct labels, the adding of additional linker domains to the primary probes of Choi et al for use in the methods rendered obvious by Choi et al in view of Cai et al would have been further obvious to one of ordinary skill in the art. The skilled artisan would recognize that where the primary probe:HCR probe interaction of Choi et al is based on the complementary sequences of the primary probe:HCR probe (e.g.: Supplementary Material of Choi et al), the detection of multiple different labels (as exemplified by Cai et al) could be augmented by the use of primary probes each with more linker domains that are the target of HCR probe hybridization. Further relevant to instantly rejected claim 87, Cai et al teaches the sequential analysis of a differently labeled probes to probe a barcoded identification of a target molecule, and Choi et al teaches the application of a plurality of probes directed to a target molecule. Where the prior art thus suggests the use of a plurality of sets of probes that are detected and identified with spectrally distinguishable labels in an HCR analysis to sequence barcodes the methods rendered obvious by the cited prior art provide for the detection of labels in a sequencing by hybridization method. Conclusion No claim is allowed. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Chen et al (2015), including the Supplementary Material, teaches methods comprising the detection of mRNA targets in situ using primary probes each with a a 5’ and 3’ linker domain and a photobleaching of a first labeled probe prior to hybridization and detection of a second labeled probe (e.g.: Fig 1). Any inquiry concerning this communication or earlier communications from the examiner should be directed to STEPHEN THOMAS KAPUSHOC whose telephone number is (571)272-3312. The examiner can normally be reached M-F, 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anne Gussow can be reached at 571-272-6047. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Stephen Kapushoc Primary Examiner Art Unit 1683 /STEPHEN T KAPUSHOC/Primary Examiner, Art Unit 1683
Read full office action

Prosecution Timeline

Jun 12, 2023
Application Filed
Oct 26, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799531
DETECTION OF GENE POLYMORPHISMS
4y 2m to grant Granted Nov 17, 2026
Patent 12716097
BIOMARKERS FOR THE DIAGNOSIS OF ATRIAL FIBRILLATION CAUSE OF STROKE
4y 2m to grant Granted Aug 25, 2026
Patent 12704520
MELANOGENESIS DETECTION METHOD USING FAM86A
4y 5m to grant Granted Aug 11, 2026
Patent 12698531
METHODS OF PREDICTING ANEURYSMS OF THE ASCENDING AND DESCENDING AORTA
3y 9m to grant Granted Aug 04, 2026
Patent 12687517
ANALYTE SEQUENCING WITH NANOPORES
2y 6m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
47%
Grant Probability
99%
With Interview (+53.7%)
3y 9m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 745 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month